

# Pharmacologic Reversal of General Anesthesia using Competitive Antagonists: Proof of Principle

Douglas E. Raines, M.D.

Edward Mallinckrodt Jr. Professor of Anaesthesia in the field of Pharmacology and Innovation

Harvard Medical School

Anesthetist

Massachusetts General Hospital



# Outline

- Competitive Antagonists
- GABA<sub>A</sub> receptor structure and ligand binding sites
- Antagonism of anesthetic action on GABA<sub>A</sub> receptors *in vitro*
- Antagonism of anesthetic action *in vivo*


# Disclosures

None

A blue-tinted photograph of surgeons in an operating room. The surgeons are wearing blue scrubs, masks, and caps. They are focused on a patient on the table. The word "None" is overlaid in the center of the image in a white, sans-serif font. The background shows the circular lights of the operating room.

# Competitive Antagonist Key Features

- Bind to the same molecular binding site as the active drug (i.e. the agonist)
- Have relatively low intrinsic efficacy (i.e. they minimally modulate target action)




# Clinically-Used Competitive Antagonists

- Naloxone (Narcan<sup>®</sup>): Opiate antagonist
- Flumazenil: Benzodiazepine antagonist
- Rocuronium: Acetylcholine antagonist





# GABA<sub>A</sub> Receptor

- Etomidate
- Propofol
- Barbiturates
- Alcohols
- Volatile agents






# Etomidate Binding Site on the $\alpha_1\beta_3\gamma_2$ GABA<sub>A</sub> Receptor




Transmembrane view

# GABA<sub>A</sub> Receptor





$\alpha_1\beta_3\gamma_2$  GABA<sub>A</sub> Receptor




Extracellular  
Domain

Transmembrane  
Domain

$\alpha_1\beta_3\gamma_2$  GABA<sub>A</sub> Receptor

Diazepam  
(at the classical  
benzodiazepine  
binding site)



Extracellular  
Domain

Transmembrane  
Domain

$\alpha_1\beta_3\gamma_2$  GABA<sub>A</sub> Receptor

Diazepam  
(at the classical benzodiazepine binding site)



Diazepam  
(at the etomidate binding site)




Diazepam  
(at the etomidate binding site)





Extracellular Domain

Transmembrane Domain



# Direct Activation of $\alpha_1\beta_3\gamma_2$ GABA<sub>A</sub> Receptors



**\*\*Diazepam has relatively low positive modulatory efficacy**


# Could Diazepam Act as a Competitive Antagonist for Etomidate at the GABA<sub>A</sub> Receptor?

## Competitive Antagonist Key Features


- Bind to the same molecular binding site as the active drug (i.e. agonist)
- Have relatively low intrinsic efficacy (i.e. they minimally modulate target action)



## nM Diazepam Concentrations




## $\mu\text{M}$ Diazepam Concentrations



At the etomidate binding site:  
Diazepam efficacy  $\ll$  Etomidate efficacy


# GABA<sub>A</sub> Receptor Electrophysiology

- Inject oocytes with RNA encoding for GABA<sub>A</sub> receptor subunits
- Clamp transmembrane potential at 50 mV.
- Directly activate receptors with etomidate (or GABA, as a control) +/- diazepam
- Record the electrophysiological response
- **Predictions:**
  - At concentrations where diazepam binds to the classical high affinity benzo site, it will potentiate both etomidate-activated and GABA-activated currents.
  - However, at concentrations where diazepam binds to the etomidate binding site, it will reduce etomidate-activated (but not GABA-activated) currents.






# GABA<sub>A</sub> Receptor Electrophysiology

- Inject oocytes with RNA encoding for GABA<sub>A</sub> receptor subunits
- Clamp transmembrane potential at 50 mV.
- Directly activate receptors with etomidate (or GABA, as a control) +/- diazepam
- Record the electrophysiological response
- **Predictions:**
  - At concentrations where diazepam binds to the classical high affinity benzo site, it will potentiate both etomidate-activated and GABA-activated currents.
  - However, at concentrations where diazepam also binds to the etomidate binding site, it will reduce etomidate-activated (but not GABA-activated) currents.







# Diazepam Potentiates at Nanomolar Concentrations But Inhibits at Micromolar Ones



# Schild Analysis Indicates Competition




# Diazepam Inhibits Photoaffinity Labeling of Purified GABA<sub>A</sub> Receptors by [<sup>3</sup>H]Azietomidate



# GABA<sub>A</sub> Receptor Summary: Diazepam Acts as a Competitive Etomidate Antagonist


- Binds to the etomidate binding site ( $K_d$ :  $\sim 10 - 20 \mu\text{M}$ )
- Low intrinsic efficacy at the GABA<sub>A</sub> receptor relative to etomidate
- Selectively antagonizes etomidate-activated currents
- Shifts the etomidate concentration-response curve for direct activation rightward
- Inhibits photolabeling of GABA<sub>A</sub> receptors by R-[<sup>3</sup>H]azietomidate.





Could Diazepam Act  
as an Etomidate  
Competitive  
Antagonist In Vivo?


# Competitive Antagonism of Etomidate Anesthesia



# Zebrafish Larvae Photomotor Response




- Steady-state drug concentrations
- Minimal effect of protein binding on free-aqueous drug concentrations
- Large number of animals can be easily studied
- Fully automated



# Zebrafish Larvae Photomotor Response

- Steady-state drug concentrations
- Minimal effect of protein binding on free-aqueous drug concentrations
- Large number of animals can be easily studied
- Fully automated





# Zebrafish Larvae Photomotor Response


Etomidate (5  $\mu$ M) alone

Etomidate (5  $\mu$ M) + Flumazenil (200  $\mu$ M)

Etomidate (5  $\mu$ M) + Flumazenil (200  $\mu$ M) + Diazepam (50  $\mu$ M)

# Competitive Antagonism of Etomidate Anesthesia


## Etomidate




$\text{EC}_{50} = 0.66 \mu\text{M} \rightarrow 12 \mu\text{M}$   
(  $p < 0.0001$  )

# Competitive Antagonism of Etomidate Anesthesia

## Etomidate




## Ketamine




# Competitive Antagonism of Etomidate Anesthesia


## Etomidate



## Ketamine




## Propofol



# Do Other Benzodiazepines Act Similarly?

**A**


5-Aryl-1,4-benzodiazepines



Name	X	Y	Z	R <sub>1</sub>	R <sub>2</sub>
Diazepam	Cl	H	H	CH <sub>3</sub>	H
Nordiazepam	Cl	H	H	H	H
Nitrazepam	NO <sub>2</sub>	H	H	H	H
Lorazepam	Cl	Cl	H	H	OH
Fludiazepam	Cl	F	H	CH <sub>3</sub>	H
1-Me	H	H	H	CH <sub>3</sub>	H
7-Me	CH <sub>3</sub>	H	H	H	H
1,4-Me	H	H	CH <sub>3</sub>	H	H
1,7-Me	H	H	CH <sub>3</sub>	CH <sub>3</sub>	H

**B**


Diazolo- and triazolo-benzodiazepines



Name	X	Y	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
Midazolam	Cl	F	CH <sub>3</sub>	C	H
Alprazolam	Cl	H	CH <sub>3</sub>	N	-
Estazolam	Cl	H	H	N	-
Imidazenil	H	Br	H	C	CONH <sub>2</sub>


**C**

Benzodiazepine antagonists




Name	X	Y
Flumazenil	F	H
Bromazenil	Br	H
lomazenil	H	I


**D**




Bromazepam




4'-2-ol




Clonazepam




Diazenil



Sulazepam





Hydrodiazenil



Medazepam



# Do Other Benzodiazepines Act Similarly?



# Summary

- Diazepam binds to the etomidate binding sites of the GABA<sub>A</sub> receptor
- Such binding competitively displaces etomidate from this site
  - Antagonizes etomidate action at the GABA<sub>A</sub> receptor *in vitro*
  - Antagonizes etomidate action *in vivo*
- Other benzodiazepines also bind to the etomidate binding site with ranging apparent affinities
- Benzodiazepines may represent a chemical template upon which GABA<sub>A</sub> receptor-selective anesthetic reversal agents can be designed

A blue-tinted photograph of two surgeons in an operating room. The surgeons are wearing blue scrubs, surgical masks, and caps. They are focused on a patient lying on the operating table. The background shows the circular lights of the operating room. The text "Thank You" is overlaid in the center in a white, sans-serif font.

Thank You